A Multicenter Randomized Open-label Trial Evaluating the Preventive Effect of Carbocisteine for Respiratory Tract Infection Induced by Chemotherapy in Japanese Non-Small Cell Lung Cancer Patients

A Multicenter Randomized Open-label Trial Evaluating the Preventive Effect of Carbocisteine for Respiratory Tract Infection Induced by Chemotherapy in Japanese Non-Small Cell Lung Cancer Patients - JACC-R Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029556

Enrollment

400

Registered

2017-10-15

Start date

2017-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer Patients

Interventions

Administration of carbocisteine 500mg three times a day for 6 months Usual care

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Lung cancer patients who receive Platinum-Based Doublet or Platinum-Based Triplet regimen as 1st line therapy

Exclusion criteria

Exclusion criteria: Patients falling under contraindications of carbocysteine administration and being carbocysteine administered continuously before the beginning of chemotherapy

Design outcomes

Primary

Measure	Time frame
Frequency of respiratory tract infection, influenza infection and febrile neutropenia at 6 months after the start of administration	—

Secondary

Measure	Time frame
Relative dose intensity of chemotherapy, Progression-free survival, Disease control rate, Peak flow and Safety at 6 months after the start of administration	—

Countries

Japan

Contacts

Public ContactYOHEI IIMURA

International University of Health and Welfare Ichikawa Hospital Department of Pharmacy

yo.0519.hei@gmail.com047-375-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026